Innovative pipeline of stereopure oligonucleotides focused on CNS diseases 32 mg data from both PRECISION-HD clinical trials on track for 2H 2020 Two.

Q1 2020 WAVE Life Sciences Ltd Earnings Call

A Cambridge startup that already had $147 million in its pocket at the end of last year is returning the Paycheck Protection Program loan it received following nationwide criticism of how the funds were awarded.

CAMBRIDGE, Mass., May 26, 2020 -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people.

The drawbacks of taking money meant for small businesses could outweigh the benefits Continue reading...

Data from both PRECISION-HD clinical trials expected in 2H 2020 Advancing clinical neurology pipeline − SNP3 and C9orf72 programs on track to initiate clinical development in.

Wave Life Sciences (WVE) delivered earnings and revenue surprises of -11.49% and -57.39%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Wave Life Sciences (WVE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Shares of WAVE Life Sciences (NASDAQ:WVE) were unchanged at $7.97 after the company reported Q1 results.Quarterly Results Earnings per share decreased 1.47% over the past year to ($1.38), which missed the estimate of ($1.20).Revenue of $4,161,000 rose by 37.51% from the same period last year, which missed the estimate of $6,050,000.Looking Ahead Earnings guidance hasn't been issued by the company for now.Revenue guidance hasn't been issued by the company for now.Details Of The Call Date: May 11, 2020View more earnings on WVETime: 07:03 PM ETWebcast URL: https://edge.media-server.com/mmc/p/evfwy3grPrice Action Company's 52-week high was at $39.9852-week low: $6.61Price action over last quarter: down 2.45%Company Description WAVE Life Sciences Ltd is a preclinical biopharmaceutical company based in Singapore. It owns a diverse pipeline of nucleic acid therapeutics meant to address rare genetic diseases related to the central nervous system, muscles, eyes, liver, and skin. Its nucleic acid therapeutics target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.See more from Benzinga * Recap: RadNet Q1 Earnings * PolarityTE: Q1 Earnings Insights * Recap: Kosmos Energy Q1 Earnings(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

In 2013 Paul Bolno was appointed CEO of Wave Life Sciences Ltd. (NASDAQ:WVE). This report will, first, examine the CEO...

Wave Life Sciences (WVE) delivered earnings and revenue surprises of -2.99% and -42.72%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

CAMBRIDGE, Mass., Feb. 13, 2020 -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people.

CAMBRIDGE, Mass., April 29, 2020 -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for.

CAMBRIDGE, Mass., Feb. 19, 2020 -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people.

Wave Life Sciences Ltd. (WVE) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

Wave Life Sciences Ltd. (WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that it has appointed Kenneth Rhodes, PhD, as Senior Vice President, Therapeutics Discovery. In this newly created position, Dr. Rhodes will be responsible for defining the strategy and guiding discovery research to design new therapeutic candidates and advance them to the clinic, with an initial focus on neurological diseases.

On the call with me here today are Dr. Paul Bolno, our President and CEO; David Gaiero, Interim CFO; Dr. Mike Panzara, our Chief Medical Officer; and Dr. Chandra Vargeese, Senior Vice President, Drug Discovery. During the first quarter, I am proud that our team's commitment along with the close partnership and support of our clinical trial site has allowed both PRECISION-HD clinical trials to continue despite the challenges presented by the COVID-19 global pandemic.

Patient deaths, testing concerns and “weak arguments.” Those are just a few of the issues the FDA had with Sarepta Therapeutics’s recent drug application, according to new documents released this week.

CAMBRIDGE, Mass., Feb. 18, 2020 -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people.

Q4 2019 WAVE Life Sciences Ltd Earnings Call